staging
Staging consists of physical examination, blood count and differential, liver and renal function tests, endoscopy and CT scan of the abdomen and pelvis and either a CXR or CT of the thorax. Endoscopic ultrasound is helpful in determining the proximal and distal extent of the tumor as well as its T stage, although it is less useful in antral tumors [III, B] . Laparoscopy with or without peritoneal washings for malignant cells should be performed in all those considered to be potentially resectable to exclude metastatic disease [III, B] . PET 
treatment plan
Multidisciplinary treatment planning is mandatory, comprising surgeons, medical and radiation oncologists, gastroenterologists, radiologists and pathologists [IV, C] .
Surgical resection is the only modality that is potentially curative, and is recommended for stages I-IVM0. The extent of optimal regional lymphadenectomy is debated. Several randomized trials have failed to show superiority of extended (D2-3) over limited (D1) lymphadenectomy, most likely due to the increased morbidity associated with the splenectomy and distal pancreatectomy performed in the studies. Conflict of interest: Dr Jackson has reported that he has received a speaking fee for a talk from Roche; Professor Cunningham has reported that he has received research funding from Roche, Sanofi-Aventis and Merck-Serono; Dr Oliveira has not reported any conflicts of interest.
the type of surgery used. Fifty-four percent of trial participants received less than a D1 dissection, although the trialists found no significant association between D-level and outcome [Ib, A] .
Meta-analyses have demonstrated a small survival benefit for adjuvant chemotherapy. [Ia, A]. In a Japanese trial of 1059 patients with completely resected stage II/III gastric cancer (Japanese classification) who underwent a D2 or greater dissection, participants were randomized to receive either 12 months of the oral fluoropyrimidine S-1 or observation alone. Twenty-seven percent did not complete the 12-month course of treatment due to adverse advents. Three-year overall survival was 70.1% in the surgery-only group and 81.1% in the group receiving adjuvant therapy. The treatment appeared to prevent mainly nodal and peritoneal relapse [Ib, A]. These results will need to be replicated in a Western population before being generalized to this group.
Treatment of patients with incompletely resected disease remains palliative.
treatment of metastatic disease
Patients with stage IV disease should be considered for palliative chemotherapy. Combination regimens incorporating a platinum agent and a fluoropyrimidine are generally used [Ia, A]. It remains controversial whether a triplet regimen is needed. However, a meta-analysis demonstrated significant benefit from adding an anthracycline to a platinum and fluoropyrimidine doublet [Ia, A], and ECF is among the most active and welltolerated regimens. Docetaxel increases the activity of 5-FU/ cisplatin, but is also clearly more toxic. Irinotecan in combination with 5-FU/LV has similar activity to 5-FU/cisplatin and can therefore also be considered in selected patients [Ib, A] .
The substitution of capecitabine (X) for 5-FU (F), and oxaliplatin (O) for cisplatin (C), in the ECF regimen was examined in a recent UK NCRI trial. With a 2·2 design, the trial tested for non-inferiority between ECF, ECX, EOF and EOX. Efficacy and toxicity was comparable between arms, and the primary end-point of non-inferiority was reached. The EOX regimen was associated with a longer overall survival (11.2 compared with 9.9 months, hazard ratio 0.80, 95% confidence interval 0.66-0.97 (P = 0.02) than the reference ECF regimen and the rate of thromboembolism was also significantly reduced by the oxaliplatin substitution at 7.6% for EOX/EOF versus 15.1% for ECX/ECF, P = 0.0003. This trial has made EOX the preferred regimen in many of the centers that were using the ECF regimen, because of the combination of improved efficacy and reduced risk of thromboembolism and relative ease of administration without the need for an indwelling venous access device [IIb] . ECX remains an option. Other studies also show that oxaliplatin can be substituted for cisplatin [Ia] and capecitabine for 5-FU in chemotherapy doublets [Ia] , preserving efficacy and offering some toxicity benefits. A recent meta-analysis has shown that capecitabine is actually superior to infused 5-FU for overall survival within doublet and triplet regimes for advanced gastric cancer [Ia, A] .
The use of cetuximab, panitumumab, bevacizumab and trastuzumab in combination with chemotherapy is being explored in clinical trials but remains experimental.
There is no standard second-line chemotherapy regimen and consideration should be given to inclusion in relevant clinical trials. Responses to regimens incorporating taxanes and irinotecan have been seen in phase II trials and are encouraging, but there are currently no data from randomized phase III trials [IIb, B] .
In patients that relapse >3 months after first-line chemotherapy, consideration should be given to re-challenging the patient with the same chemotherapy regimen [IV, C].
follow-up
There is no evidence that regular intensive follow-up improves patient outcomes. Symptom-driven visits are recommended for most cases [III, B] .
If symptoms of relapse occur, patient history, physical examination and directed blood tests should be performed. Radiological investigations should be performed in patients who are candidates for palliative chemo-or radiotherapy [IV, C]. 
